Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs Organon & Co. Common Stock (OGN) Price & Performance

NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)Trade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) vs Organon & Co. Common Stock — how do they compare? NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.57 (market cap $69.79B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 19.3× Organon & Co. Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays the higher dividend (5.34%). Which is the better fit depends on your goals — on Pluang, investors hold NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 3 Days and Organon & Co. Common Stock for 0 Days on average.

NWGOGN
Market Cap
$69.79B$3.62B
Volume
3,183,9822,892,999
Sector
FinancialsHealth
52-Week High
$19.42$13.81
52-Week Low
$13.89$5.70
Typical Hold Time
3 Days0 Days
Enterprise Value
$142.57B$11.04B
Dividend Yield
5.34%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)

NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.

The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NWG

No sentiment data available yet.

OGN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)

NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.

Read more on NWG →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →